Evidence map›Paper›PMID 42243148›Full record

ArticleNature communications2026

The cumulative impact of passenger mutations on cancer development.

Akshatha Nayak, Candace S Y Chan, Ioannis Mouratidis, Ilias Georgakopoulos-Soares

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Akshatha NayakDivision of Pharmacology and Toxicology, College of Pharmacy, Dell Pediatric Research Institute, The University of Texas at Austin, Austin, TX, USA.
Candace S Y ChanDivision of Pharmacology and Toxicology, College of Pharmacy, Dell Pediatric Research Institute, The University of Texas at Austin, Austin, TX, USA.ORCID http://orcid.org/0000-0001-9667-7996
Ioannis MouratidisDivision of Pharmacology and Toxicology, College of Pharmacy, Dell Pediatric Research Institute, The University of Texas at Austin, Austin, TX, USA.ORCID http://orcid.org/0000-0002-1025-8780
Ilias Georgakopoulos-SoaresDivision of Pharmacology and Toxicology, College of Pharmacy, Dell Pediatric Research Institute, The University of Texas at Austin, Austin, TX, USA. ilias@austin.utexas.edu.ORCID http://orcid.org/0000-0003-3641-1488

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The traditional binary classification of somatic mutations in cancer as either drivers or passengers overlooks the potential cumulative impact of smaller-effect mutations. Here, we analyze more than 11,000 whole-genome-sequenced primary tumors across 3 cancer cohorts to assess the functional contribution of passenger mutations in cancer development. We find that in the absence of canonical driver mutations, passenger mutations in cancer genes are significantly enriched, exhibit higher predicted pathogenicity, and are associated with aberrant expression, splicing disruption, altered transcription factor binding, and clinical outcomes that resemble those in the presence of driver mutations. The accumulation of passenger mutations in tumor suppressor genes correlates with significantly reduced expression and poorer prognosis, suggesting that progressive mutational burden may contribute to gradual impairment of tumor suppressor function, mirroring the functional outcomes of driver mutations. Together, these results support a continuum model of mutational impact, where the collective influence of passenger mutations contributes to oncogenesis and clinical outcomes. This work advocates for integrative cancer models that incorporate all somatic mutations to more accurately reflect the complexity of tumor evolution.

Indexed as

CarcinogenesisMutationNeoplasmsGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansPrognosisWhole Genome Sequencing

Identifiers

PMID42243148
PMCPMC13396589

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.